Shares of Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $32.17.
A number of analysts recently weighed in on the stock. HC Wainwright increased their price target on shares of Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Oppenheimer reissued an “outperform” rating on shares of Q32 Bio in a research report on Thursday, October 1st. Mizuho upgraded shares of Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Weiss Ratings cut shares of Q32 Bio from a “hold (c)” rating to a “sell (d+)” rating in a report on Monday, November 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Q32 Bio in a research note on Wednesday, September 16th.
Check Out Our Latest Research Report on QTTB
Q32 Bio Trading Down 4.8%
Q32 Bio (NASDAQ:QTTB – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.07. Research analysts predict that Q32 Bio will post -1.42 EPS for the current fiscal year.
Insider Activity at Q32 Bio
In other Q32 Bio news, CEO Jodie Morrison sold 9,845 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the sale, the chief executive officer directly owned 343,259 shares of the company’s stock, valued at $5,684,369.04. This represents a 2.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia Violette sold 2,798 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $46,334.88. Following the sale, the insider directly owned 127,771 shares of the company’s stock, valued at $2,115,887.76. The trade was a 2.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 22,054 shares of company stock worth $320,397 in the last quarter. Company insiders own 34.46% of the company’s stock.
Institutional Investors Weigh In On Q32 Bio
Several large investors have recently modified their holdings of the stock. Atlas Venture Life Science Advisors LLC raised its stake in shares of Q32 Bio by 29.9% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company’s stock worth $34,616,000 after purchasing an additional 625,000 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Q32 Bio by 450.3% during the third quarter. Marshall Wace LLP now owns 368,935 shares of the company’s stock worth $3,051,000 after purchasing an additional 301,890 shares during the period. Goldman Sachs Group Inc. purchased a new position in Q32 Bio in the 3rd quarter valued at $2,387,000. BlackRock Inc. purchased a new position in Q32 Bio in the 2nd quarter valued at $1,510,000. Finally, Renaissance Technologies LLC grew its position in Q32 Bio by 107.7% in the 1st quarter. Renaissance Technologies LLC now owns 206,915 shares of the company’s stock valued at $1,328,000 after buying an additional 107,315 shares during the last quarter. Hedge funds and other institutional investors own 31.32% of the company’s stock.
Q32 Bio Company Profile
Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.
Featured Stories
- Five stocks we like better than Q32 Bio
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.
